Accessibility Menu
Shuttle Pharmaceuticals logo

Shuttle Pharmaceuticals(NASDAQ) SHPH

Current Price$2.85
Market Cap$1.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-92%
1 Month-22%
Shuttle Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 2.992026-07-23
Shuttle Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.77%USD 3.552026-07-16
1 month-22.14%USD 3.842026-06-23
3 month-70.97%USD 10.302026-04-24
Year to date-83.39%USD 18.002025-12-31
1 year-92.47%USD 39.702025-07-23
3 year-99.84%USD 1,880.002023-07-24
Since inception-100%USD 76,960.002022-08-31

Shuttle Pharmaceuticals Financials at a Glance

Market Cap

$1.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$10.82M

EPS (TTM)

-$60.62

P/E Ratio

-0.05

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$2.85

Volume

87,581

Open

$2.93

Previous Close

$2.89

Daily Range

$2.78 - $2.93

52-Week Range

$2.71 - $55.90

Estimated Earnings Date

May 14, 2026

SHPH News

healthcare lab treatment research scientist

Why Shares of Shuttle Pharmaceuticals Jumped 160.4% This Week

James HalleySep 9, 2022

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shuttle Pharmaceuticals

Shuttle Pharma develops drugs and software to help treat cancer. Its products aim to make radiation therapy more effective for patients. The company also offers artificial intelligence tools for drug discovery in healthcare research.

Products and Services

  • Drug Development: Creates drugs to make cancer cells more sensitive to radiation; 0% of revenue as of 2025.
  • AI Software Platform: Molecule.ai uses artificial intelligence to help scientists discover new drugs; 0% of revenue as of 2025.
  • Research Partnerships: Collaborates with universities for cancer drug research; 0% of revenue as of 2025.

Growth and Expansion

  • Acquired Molecule.ai in November 2025 to add AI drug discovery tools.
  • Ended clinical trials for main drug candidate, Ropidoxuridine, in late 2025.
  • Expanded research with the University of California, San Francisco in 2025.
  • Raised over $10 million through equity offerings in 2025 and early 2026.

What Makes Shuttle Pharma Stand Out

The company shifted from drug development to AI-driven drug discovery. Its Molecule.ai platform supports early-stage research for scientists. Shuttle Pharma focuses on licensing technology rather than selling drugs directly.

Five Things You Need to Know

  • No revenue reported for 2025, 2024, or 2023.
  • Net loss was $11.7 million in 2025, up 28% from 2024.
  • Operating expenses rose 55% to $11.9 million in 2025.
  • Cash and equivalents fell 83% to $0.3 million by end of 2025.
  • Working capital deficit reached $7.5 million as of December 2025.

Bottom Line

Shuttle Pharma is moving from drug development to AI-powered research tools. The company faces ongoing losses and relies on new funding to operate.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Christopher Robert Cooper, MBA

Website

www.shuttlepharma.com

Headquarters

Gaithersburg, MD 20850, US

SHPH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-408.33%

Return on Capital

-479.24%

Return on Assets

-91.63%

Earnings Yield

-20.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

637.10K

Volume

87.58K

Avg. Volume

2.17M

Financials (TTM)

Gross Profit

-$922.41K

Operating Income

-$11.18M

EBITDA

-$9.83M

Operating Cash Flow

-$9.37M

Capital Expenditure

$4.00

Free Cash Flow

-$9.37M

Cash & ST Invst.

$1.09M

Total Debt

$214.01K

Shuttle Pharmaceuticals Performance Analysis

Shuttle Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Shuttle Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Shuttle Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,260.92582.4%
20232023-12-31USD -883.14-30.0%
20242024-12-31USD -826.03-6.5%
20252025-12-31USD -71.56-91.3%
Shuttle Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-338.7%
Q32025-09-3068.1%
Q42025-12-31-22.9%
Q12026-03-3166.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$633.34K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$952.50K

N/A

Employees

2

N/A

Net Income

-$2.15M

+29.5%

EBITDA

-$1.51M

+50.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.09M

-75.8%

Total Debt

$214.01K

-80.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$134.05K

-39.1%

Short Term Debt

$79.96K

-91.0%

Return on Assets

-91.63%

N/A

Return on Invested Capital

-3.19%

N/A

Free Cash Flow

-$2.42M

+4.3%

Operating Cash Flow

-$2.42M

+4.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BBLGBone Biologics Corporation
$1.07-0.93%
RDHLRedHill Biopharma Ltd.
$0.63-5.22%
UPCUniverse Pharmaceuticals Inc.
$3.39-10.55%
IMCCIM Cannabis Corp.
$0.12-12.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.00-0.03%

Questions About SHPH

What is the current price of Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals is trading at $2.89 per share.

What is the 52-week range for Shuttle Pharmaceuticals?

Over the past 52 weeks, Shuttle Pharmaceuticals has traded between $2.71 and $55.90.

How much debt does Shuttle Pharmaceuticals have?

As of the most recent reporting period, Shuttle Pharmaceuticals reported total debt of $214.01K.

How much cash does Shuttle Pharmaceuticals have on hand?

Shuttle Pharmaceuticals reported $1.09M in cash and cash equivalents in its most recent financial results.

What is Shuttle Pharmaceuticals’s dividend yield?

Shuttle Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services